@inproceedings{inproceedings, title  = {{Non-myeloablative hematopoietic stem cell transplantation (HSCT) is superior to disease modifying drug (DMD) treatment in highly active Relapsing Remitting Multiple Sclerosis (RRMS): interim results of the Multiple Sclerosis International Stem cell Transplant (MIST) Randomized Trial (S36.004)}},

 publisher = {{Ovid Technologies (Wolters Kluwer Health)}},

 url = {{https://doi.org/10.1212/wnl.90.15_supplement.s36.004 }},

 year = {{2018}},

 month = {{4}},

 author = {{Burt RK and Balabanov R and Snowden JA and Sharrack B and Oliveira MC and Burman J}},

 doi = {{10.1212/wnl.90.15_supplement.s36.004}},

 volume = {{90}},

 journal = {{Neurology}},

 issue = {{15_supplement}},

 note = {{Accessed on 2025/11/15}}}